IOV-COM-202 patient treatment schema. CY, cyclophosphamide; EOA, end of assessment; EOS, end of study; EOT, end of treatment; FLU, fludarabine; GMP, Good Manufacturing Practice; NMA-LD, nonmyeloablative lymphodepletion; TIL, tumor-infiltrating lymphocytes.
No takes yet. Share an insight, caveat, or question.
Schoenfeld et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: